Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

FDA grants Inovio's Voceryq (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd) accelerated approval for recurrent respiratory papillomatosis based on Ph1/Ph2 data
Gene therapy, infectious disease, DNA plasmid, recurrent respiratory papillomatosis, HPV, immunotherapy - Read more

Fresenius, WuXi Biologics strike exclusive biosimilar deal for up to 37 candidates targeting €370B ($412.7B) market
Licensing deal, biosimilars, antibody, fee-for-service, drug discovery - Read more

Biossil Labs acquires Theriva Biologics' antibiotic degrader portfolio for up to $91M
Licensing deal, infectious disease, AI/ML, small molecule, milestone payments, royalties - Read more

Bavarian Nordic awarded multi-year MVA-BN vaccine supply contract by UK government for mpox and smallpox preparedness
Manufacturing agreement, vaccine, infectious disease, public health preparedness - Read more

Alligator Bioscience sells mitazalimab rights to Biossil, $0.75M upfront, up to $108M milestones
Asset sale, oncology, antibody, milestone payments, royalties - Read more

Science 2 Sales is the outbound engine for companies selling into biotech & pharma. We handle the market intelligence, prospect scoring, email sequences, LinkedIn outreach, and cold calling - so your sales team inherits a full calendar of qualified meetings.

Built by biopharma BD & sales reps, exclusively for biopharma commercial teams. It’s the platform and service we wish we had years ago.

Learn more and book a free strategy call on our website.

Tiziana Life Sciences' (foralumab) hits Ph2a primary endpoints at lower dose for non-active secondary progressive multiple sclerosis
Antibody, neurological, monoclonal antibody, multiple sclerosis, anti-CD3, microglial activation - Read more

InventisBio's (nomelcitinib) TYK2 inhibitor meets primary endpoint in Ph3 plaque psoriasis trial
Small molecule, autoimmune, TYK2 inhibitor, psoriasis - Read more

AbbVie reports Skyrizi psoriasis share unaffected by Johnson & Johnson's Icotyde, sales up 23%
Monoclonal antibody, autoimmune, competitive, revenue impact - Read more

Atlas Bio raises $11M seed funding, scaling AI platform for in silico clinical trials
AI/ML platform, in silico clinical trials, drug discovery, platform technology - Read more

FDA accepts uniQure's (ifezuntirgene inilparvovec) biologics license application for Huntington's disease with priority review
Gene therapy, neurological, Huntington's disease, AAV vector, ifezuntirgene inilparvovec - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

Teva, Modag's (emrusolmin) Ph2 trial halted over futility in multiple system atrophy
Small molecule, neurological, multiple system atrophy, neurodegeneration, phase 2 trial, futility - Read more

Karyopharm Therapeutics files Chapter 11, names Ayrmid as lead bidder in planned merger
Small molecule, hematology, major transaction, financial - Read more

FDA places partial clinical hold on Bright Minds Biosciences' seizure trial over mouse toxicity concerns, shares drop 49%
Small molecule, epilepsy, regulatory, operational - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here